Lekarze w leczeniu Guz nadnercza za granicą — Strona 3

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Doc. dr Nail Paksoy łączy ponad 11-letnie specjalistyczne doświadczenie onkologiczne z aktywnym udziałem w 8 międzynarodowych badaniach klinicznych w szpitalu Medipol Bahçelievler.

• Posiada certyfikat ESMO w zakresie onkologii klinicznej
• Specjalizuje się w leczeniu guzów nadnerczy oraz rzadkich typów nowotworów
• Opublikował ponad 30 recenzowanych prac naukowych na temat metod leczenia onkologicznego
• Ukończył staż specjalizacyjny w Instytucie Onkologii Uniwersytetu Stambulskiego

Przeszedł szkolenie w zakresie zaawansowanej chirurgii laparoskopowej na Uniwersytecie Stambulskim. Specjalizuje się w małoinwazyjnych zabiegach usuwania guzów nadnerczy.

• Ponad 20 lat doświadczenia chirurgicznego
• Ukończył specjalistyczne szkolenie w zakresie laparoskopowej chirurgii bariatrycznej oraz onkologicznej
• Pracuje w Szpitalach Büyük Anadolu – wiodącym centrum medycznym

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Dr Volkan Kinas specjalizuje się w chirurgii onkologicznej, koncentrując się na skomplikowanych przypadkach nowotworów w Szpitalach Büyük Anadolu.

• Ekspert w operacjach nowotworów trzustki, dróg żółciowych oraz nadnerczy
• Biegły w technikach tradycyjnych oraz małoinwazyjnych
• Przeprowadza operacje nowotworów piersi, żołądka i jelita grubego

Specjalizował się w onkologii radioterapeutycznej na Uniwersytecie Marmara — odbył specjalistyczne szkolenie w zakresie zaawansowanych metod leczenia nowotworów nadnerczy.

• Posiada ponad 6-letnie specjalistyczne doświadczenie w onkologii radioterapeutycznej
• Ukończył Wydział Lekarski Uniwersytetu Marmara (program anglojęzyczny)
• Pracuje w szpitalu Emsey, wiodącej placówce w zakresie opieki onkologicznej

Prof. Filippini specjalizuje się w leczeniu chirurgicznym nowotworów miejscowo zaawansowanych oraz resekcjach wielonarządowych. Doświadczenie zdobywał w czołowych amerykańskich ośrodkach, takich jak Memorial Sloan Kettering.

• Ponad 40 lat doświadczenia w chirurgii onkologicznej
• Przeszkolony w zakresie technik małoinwazyjnych i robotycznych w USA
• Autor ponad 100 publikacji naukowych
• Profesor na Uniwersytecie w Chieti od lat 90.

Profesor Ahmet Cag Cal posiada wieloletnie doświadczenie w urologii specjalistycznej. Swoje umiejętności doskonalił m.in. w Memorial Sloan-Kettering Cancer Center oraz UCLA.

• Ponad 30 lat praktyki urologicznej
• Ukończył staż specjalistyczny (fellowship) w Mayo Clinic w Minnesocie
• Obecnie zajmuje stanowisko profesora w szpitalu Medicana Bursa
• Specjalizuje się w złożonych zabiegach urologicznych
• Publikuje prace badawcze z zakresu urologii i genetyki molekularnej

Dr Shruti Kate specjalizuje się w leczeniu nowotworów nadnerczy, kładąc szczególny nacisk na immunoterapię oraz terapię metronomiczną w zaawansowanych stadiach choroby. Swoje doświadczenie zdobywała w Tata Memorial Hospital, jednym z czołowych ośrodków onkologicznych w Indiach.

• Posiada stopień DM w dziedzinie onkologii klinicznej uzyskany w Tata Memorial Hospital
• Jest ekspertem w zakresie leczenia raka płuc, piersi oraz nowotworów układu moczowo-płciowego
• Jest członkiem ASCO, ESMO oraz innych prestiżowych towarzystw onkologicznych
• Prezentowała badania naukowe na Światowej Konferencji Raka Płuca